Sensus Healthcare Inc. reported revenues of $6.9 million for the third quarter of 2025. The company recorded a net loss of $0.9 million, or $0.06 per share, for the quarter. For the first nine months of 2025, revenues were $22.5 million, down 21.6% from $28.7 million in the same period of 2024. Net loss for the nine-month period was $4.6 million, or $0.28 per share, compared to net income of $5.1 million, or $0.31 per diluted share, in the first nine months of 2024. Sensus shipped 16 SRT systems in the third quarter, including 10 to a large customer and three internationally, bringing total units sold for the nine months to 56, compared to 76 in the same period last year. The company exited the quarter with $24.5 million in cash and no debt. CMS established coding validating SRT for treating non-melanoma skin cancer during the period. The Fair Deal Agreement treatment volume increased by 20% over the previous quarter. Research and development expenses rose to $5.9 million for the first nine months of 2025, primarily due to lobbying costs, higher headcount, and product development. Cost of sales for the nine months was $12.6 million, up from $11.4 million in the same period of 2024.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensus Healthcare Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106691166) on November 06, 2025, and is solely responsible for the information contained therein.
Comments